Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 27, 2024; 16(1): 109-111
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.109
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.109
Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients
Yu-Tong Sun, Qian-Qian Chen, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing 100193, China
Author contributions: Sun YT drafted the article; Chen QQ made critical revisions related to important intellectual content of the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qian-Qian Chen, MD, Associate Chief Physician, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100193, China. qian_qian_chen@163.com
Received: October 30, 2023
Peer-review started: October 30, 2023
First decision: November 22, 2023
Revised: December 4, 2023
Accepted: January 12, 2024
Article in press: January 12, 2024
Published online: January 27, 2024
Processing time: 84 Days and 21.7 Hours
Peer-review started: October 30, 2023
First decision: November 22, 2023
Revised: December 4, 2023
Accepted: January 12, 2024
Article in press: January 12, 2024
Published online: January 27, 2024
Processing time: 84 Days and 21.7 Hours
Core Tip
Core Tip: With the significant increase in the incidence of nonalcoholic fatty liver disease (NAFLD) in China, the number of patients with co-morbid chronic hepatitis B (CHB) and NAFLD has gradually increased. This letter comments on a published study which showned that CHB patients treated with tenofovir alafenamide (TAF) had higher levels of total cholesterol than CHB patients treated with entecavir; however, TAF-induced dyslipidemia did not increase the incidence of NAFLD. We comment on the article.